as 05-17-2024 4:00pm EST
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Founded: | 2011 | Country: | United States |
Employees: | N/A | City: | VANCOUVER |
Market Cap: | 589.2M | IPO Year: | 2021 |
Target Price: | $9.25 | AVG Volume (30 days): | 1.3M |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.16 | EPS Growth: | N/A |
52 Week Low/High: | $1.11 - $6.72 | Next Earning Date: | 05-14-2024 |
Revenue: | $5,347,000 | Revenue Growth: | -13.72% |
Revenue Growth (this year): | 95.51% | Revenue Growth (next year): | 119.80% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Redmile Group, LLC | ABSI | Director | Mar 1 '24 | Buy | $4.50 | 222,222 | $999,999.00 | 8,253,316 | SEC Form 4 |
ABSI Breaking Stock News: Dive into ABSI Ticker-Specific Updates for Smart Investing
GuruFocus.com
5 days ago
GlobeNewswire
6 days ago
Zacks
12 days ago
Zacks
17 days ago
GlobeNewswire
a month ago
Zacks
a month ago
GlobeNewswire
2 months ago
GuruFocus.com
2 months ago